Claims
- 1. A method of inhibiting Vif multimerization in a subject by administering an effective amount of a Vif antagonist to the subject, wherein the Vif antagonist binds to the multimerization domain within a Vif protein.
- 2. The method of claim 1, wherein the Vif antagonist is an anti-Vif antibody; a Vif protein fragment which comprises at least SEQ ID NO: 25; or a peptide comprising a PXP motif.
- 3. The method of claim 2, wherein the Vif antagonist is an anti-Vif antibody.
- 4. The method of claim 2, wherein the Vif protein fragment is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 26.
- 5. The method of claim 1, wherein the Vif antagonist is an analog or derivative of a Vif protein fragment which comprises at least SEQ ID NO: 25.
- 6. The method of claim 1, wherein the Vif antagonist is a chimeric protein comprising a Vif protein, or a chimeric protein comprising a Vif protein fragment which comprises at least SEQ ID NO: 25.
- 7. The method of claim 2, wherein the Vif antagonist is a peptide comprising a PXP motif.
- 8. The method of claim 7, wherein X in the PXP motif is any one amino acid.
- 9. The method of claim 8, wherein the any one amino acid selected from the group consisting of Arg, Val, Pro, Ser, Leu, Phe, Ala, His and Tyr.
- 10. The method of claim 7, wherein X in the PXP motif is any two amino acids.
- 11. The method of claim 10, wherein the any two amino acids are Pro-Pro or Pro-Leu.
- 12. The method of claim 7, wherein the peptides comprising the PXP motif are 4 to 20 amino acids long.
- 13. The method of claim 12, wherein the peptides comprising the PXP motif are 5 to 20 amino acids long.
- 14. The method of claim 12, wherein the peptides comprising the PXP motif are 12 amino acids long.
- 15. The method of claim 7, wherein the peptides comprising the PXP motif are selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.
- 16. The method of claim 1, wherein the Vif antagonist is a peptidomimetic of a peptide comprising a PXP motif.
- 17. The method of claim 1, wherein the Vif antagonist is a molecule comprising one or more peptides comprising a PXP motif.
- 18. The method of claim 1, wherein the Vif antagonist is a molecule comprising one or more peptidomimetics of peptides comprising a PXP motif.
- 19. The method of claim 1, wherein the Vif antagonist is administered parenterally or enterally.
- 20. The method of claim 1, wherein the Vif antagonist is administered locally.
CONTINUING APPLICATION DATA
[0001] This application is a divisional of U.S. application No. 10/118,575, filed Apr. 8, 2002 which claims priority to U.S. provisional application number 60/282,270, filed Apr. 6, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60282270 |
Apr 2001 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
10118575 |
Apr 2002 |
US |
Child |
10688100 |
Oct 2003 |
US |